false
English
Catalog
2021 World Conference on Lung Cancer (Posters)
FP04. RATIONALE-307: Updated Biomarker Analysis of ...
FP04. RATIONALE-307: Updated Biomarker Analysis of Phase 3 Study of Tislelizumab Plus Chemo vs Chemo Alone For 1L Advanced Sq-NSCLC
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
Zhijie Wang presented an updated biomarker analysis of Rational 307, a phase 3 study of T-selizomib plus chemotherapy versus chemotherapy alone for first-line advanced squamous non-small cell lung cancer. The analysis evaluated biomarkers including PD-L1 expression, tumor mutation burden (TMB), and tumor inflammation signature (TIS). The results showed that T-selizomib plus chemotherapy provided a significantly prolonged progression-free survival (PFS) compared to chemotherapy alone, regardless of PD-L1 expression, tissue TMB, and blood TMB status. Additionally, the TIS score was significantly associated with PFS benefit, highlighting the importance of the tumor microenvironment in the clinical benefit of combination treatment.
Asset Subtitle
Jie Wang
Meta Tag
Speaker
Jie Wang
Topic
Immunotherapy (Phase II/III Trials)
Keywords
Zhijie Wang
biomarker analysis
Rational 307
T-selizomib
chemotherapy
×
Please select your language
1
English
5
普通话
11
Dutch